Mark J DiNubile

Summary

Affiliation: Merck Research Laboratories
Country: USA

Publications

  1. ncbi request reprint Efficacy and safety of ertapenem versus piperacillin-tazobactam for the treatment of intra-abdominal infections requiring surgical intervention
    Arturo S Dela Pena
    Philippine General Hospital, Manila, Philippines
    J Gastrointest Surg 10:567-74. 2006
  2. ncbi request reprint Nodular lymphangitis: a distinctive clinical entity with finite etiologies
    Mark J DiNubile
    Merck Research Laboratories, UG3C 06, PO Box 1000, North Wales, PA 19454, USA
    Curr Infect Dis Rep 10:404-10. 2008
  3. ncbi request reprint Ertapenem versus cefepime for initial empirical treatment of pneumonia acquired in skilled-care facilities or in hospitals outside the intensive care unit
    S V Yakovlev
    Municipal Hospital 7, Moscow, and Smolensk State Medical Academy, Russia
    Eur J Clin Microbiol Infect Dis 25:633-41. 2006
  4. doi request reprint Double-blind active-control trials: beware the comparator you keep
    Mark J DiNubile
    Merck Research Laboratories, West Point, Pennsylvania, USA
    Clin Infect Dis 47:1064-7. 2008
  5. ncbi request reprint Bowel colonization with vancomycin-resistant enterococci after antimicrobial therapy for intra-abdominal infections: observations from 2 randomized comparative clinical trials of ertapenem therapy
    Mark J DiNubile
    Merck and Co, Inc, Whitehouse Station, NJ, USA
    Diagn Microbiol Infect Dis 58:491-4. 2007
  6. pmc Acquisition of resistant bowel flora during a double-blind randomized clinical trial of ertapenem versus piperacillin-tazobactam therapy for intraabdominal infections
    Mark J DiNubile
    Merck Research Laboratories, P O Box 4, BL3 4, West Point, PA 19486, USA
    Antimicrob Agents Chemother 49:3217-21. 2005
  7. ncbi request reprint Bowel colonization with resistant gram-negative bacilli after antimicrobial therapy of intra-abdominal infections: observations from two randomized comparative clinical trials of ertapenem therapy
    M J DiNubile
    Merck and Co, Whitehouse Station, NJ, USA
    Eur J Clin Microbiol Infect Dis 24:443-9. 2005
  8. ncbi request reprint Invasive candidiasis treated in the intensive care unit: observations from a randomized clinical trial
    Mark J DiNubile
    Department of Medical Communication, Merck Research Laboratories, West Point, PA 19486, USA
    J Crit Care 22:237-44. 2007
  9. ncbi request reprint Complicated infections of skin and skin structures: when the infection is more than skin deep
    Mark J DiNubile
    Merck Research Laboratories, BL 3 4, PO Box 4, West Point, PA 19486, USA
    J Antimicrob Chemother 53:ii37-50. 2004
  10. ncbi request reprint Invasive candidiasis in cancer patients: observations from a randomized clinical trial
    Mark J DiNubile
    Department of Clinical Research, Merck Research Laboratories, P O Box 4, BL3 4, West Point, PA 19486, USA
    J Infect 50:443-9. 2005

Detail Information

Publications53

  1. ncbi request reprint Efficacy and safety of ertapenem versus piperacillin-tazobactam for the treatment of intra-abdominal infections requiring surgical intervention
    Arturo S Dela Pena
    Philippine General Hospital, Manila, Philippines
    J Gastrointest Surg 10:567-74. 2006
    ..In this study, ertapenem and piperacillin/tazobactam were comparably safe and effective treatments for adult patients with complicated intra-abdominal infections...
  2. ncbi request reprint Nodular lymphangitis: a distinctive clinical entity with finite etiologies
    Mark J DiNubile
    Merck Research Laboratories, UG3C 06, PO Box 1000, North Wales, PA 19454, USA
    Curr Infect Dis Rep 10:404-10. 2008
    ..A detailed history and clues from the physical examination, supplemented by biopsy specimens in selected circumstances, should allow specific therapy for most patients...
  3. ncbi request reprint Ertapenem versus cefepime for initial empirical treatment of pneumonia acquired in skilled-care facilities or in hospitals outside the intensive care unit
    S V Yakovlev
    Municipal Hospital 7, Moscow, and Smolensk State Medical Academy, Russia
    Eur J Clin Microbiol Infect Dis 25:633-41. 2006
    ..In this study population, ertapenem was as well-tolerated and efficacious as cefepime for the initial treatment of pneumonia acquired in skilled-care facilities or in hospital environments outside the ICU...
  4. doi request reprint Double-blind active-control trials: beware the comparator you keep
    Mark J DiNubile
    Merck Research Laboratories, West Point, Pennsylvania, USA
    Clin Infect Dis 47:1064-7. 2008
    ..In phase II/III blinded, active-control trials, the reporting of adverse experiences attributed to a first-in-class drug might be confounded to a variable degree by expectations regarding a well-known comparator...
  5. ncbi request reprint Bowel colonization with vancomycin-resistant enterococci after antimicrobial therapy for intra-abdominal infections: observations from 2 randomized comparative clinical trials of ertapenem therapy
    Mark J DiNubile
    Merck and Co, Inc, Whitehouse Station, NJ, USA
    Diagn Microbiol Infect Dis 58:491-4. 2007
    ..In these short-term studies, overall rates of bowel colonization with VRE were generally comparable after treatment with piperacillin-tazobactam, ceftriaxone/metronidazole, or ertapenem...
  6. pmc Acquisition of resistant bowel flora during a double-blind randomized clinical trial of ertapenem versus piperacillin-tazobactam therapy for intraabdominal infections
    Mark J DiNubile
    Merck Research Laboratories, P O Box 4, BL3 4, West Point, PA 19486, USA
    Antimicrob Agents Chemother 49:3217-21. 2005
    ..6%; P = 0.10). In this study, the acquisition of resistant Enterobacteriaceae occurred significantly more often in patients treated with piperacillin-tazobactam than in those treated with ertapenem...
  7. ncbi request reprint Bowel colonization with resistant gram-negative bacilli after antimicrobial therapy of intra-abdominal infections: observations from two randomized comparative clinical trials of ertapenem therapy
    M J DiNubile
    Merck and Co, Whitehouse Station, NJ, USA
    Eur J Clin Microbiol Infect Dis 24:443-9. 2005
    ....
  8. ncbi request reprint Invasive candidiasis treated in the intensive care unit: observations from a randomized clinical trial
    Mark J DiNubile
    Department of Medical Communication, Merck Research Laboratories, West Point, PA 19486, USA
    J Crit Care 22:237-44. 2007
    ....
  9. ncbi request reprint Complicated infections of skin and skin structures: when the infection is more than skin deep
    Mark J DiNubile
    Merck Research Laboratories, BL 3 4, PO Box 4, West Point, PA 19486, USA
    J Antimicrob Chemother 53:ii37-50. 2004
    ..Surgical debridement is important for many complicated infections, and is the critical element in managing necrotizing fasciitis and myonecrosis...
  10. ncbi request reprint Invasive candidiasis in cancer patients: observations from a randomized clinical trial
    Mark J DiNubile
    Department of Clinical Research, Merck Research Laboratories, P O Box 4, BL3 4, West Point, PA 19486, USA
    J Infect 50:443-9. 2005
    ..Invasive candidiasis is a common and serious complication of cancer and its therapy...
  11. doi request reprint Efficacy and safety of caspofungin therapy in elderly patients with proven or suspected invasive fungal infections
    M J DiNubile
    Merck Research Laboratories, West Point, PA, USA
    Eur J Clin Microbiol Infect Dis 27:663-70. 2008
    ..In this post-hoc analysis, caspofungin appeared to be as efficacious and well tolerated in elderly patients as in non-elderly patients...
  12. ncbi request reprint Response and relapse rates of candidal esophagitis in HIV-infected patients treated with caspofungin
    Mark J DiNubile
    Merck Research Laboratories, West Point, Pennsylvania 19486, USA
    AIDS Res Hum Retroviruses 18:903-8. 2002
    ..In this relatively small number of patients, only symptom severity and extent of disease judged endoscopically at baseline were significantly (p < 0.10) associated with early relapse in the multivariate model...
  13. ncbi request reprint Prognostic implications of declining plasma gelsolin levels after allogeneic stem cell transplantation
    Mark J DiNubile
    Division of Infectious Diseases, Department of Medicine, University of Medicine and Dentistry of New Jersey Robert Wood Johnson Medical School, Camden, NJ, USA
    Blood 100:4367-71. 2002
    ..0007). These findings suggest that gelsolin levels shortly after allogeneic HSCT can predict the later development of fatal IPS. Gelsolin replacement in selected transplant patients may offer a novel strategy to prevent or reverse IPS...
  14. ncbi request reprint In vitro susceptibilities of aerobic and facultative gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: the 2002 Study for Monitoring Antimicrobial Resistance Trends (SMART)
    Joseph W Chow
    Merck Research Laboratories, West Point, Pennsylvania 19486 0004, USA
    Surg Infect (Larchmt) 6:439-48. 2005
    ..The Study for Monitoring Antimicrobial Resistance Trends (SMART) was begun in 2002 to monitor international drug-resistance patterns among aerobic and facultative gram-negative bacilli isolated from patients with intra-abdominal infections...
  15. doi request reprint Sustained decline in cases of rotavirus gastroenteritis presenting to the Children's Hospital of Philadelphia in the new rotavirus vaccine era
    H Fred Clark
    Division of Infectious Diseases, The Children s Hospital of Philadelphia, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    Pediatr Infect Dis J 29:699-702. 2010
    ..To exclude the possibility that factors other than vaccination accounted for the declining case frequency, we examined the 2008 to 2009 experience at the Children's Hospital of Philadelphia (CHOP)...
  16. doi request reprint Distribution of rotavirus genotypes causing nosocomial and community-acquired acute gastroenteritis at the Children's Hospital of Philadelphia in the new rotavirus vaccine era
    H Fred Clark
    The Children s Hospital of Philadelphia CHOP, Philadelphia, PA, USA
    Hum Vaccin 7:1118-23. 2011
    ..We examined whether serotype replacement was occurring as a result of vaccine use...
  17. ncbi request reprint Efficacy of caspofungin in the treatment of esophageal candidiasis resistant to fluconazole
    Nicholas Kartsonis
    Merck Research Laboratories, West Point, Pennsylvania 19486, USA
    J Acquir Immune Defic Syndr 31:183-7. 2002
    ..Caspofungin appeared to be efficacious therapy for some patients with esophageal candidiasis who were clinically refractory to fluconazole or infected by with reduced susceptibility to fluconazole in vitro...
  18. ncbi request reprint Efficacy, safety, and tolerability of long-term combination antiretroviral therapy in asymptomatic treatment-naïve adults with early HIV infection
    Deborah K McMahon
    University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
    HIV Clin Trials 8:269-81. 2007
    ....
  19. ncbi request reprint Ertapenem as initial antimicrobial monotherapy for patients with chronic obstructive pulmonary disease hospitalized with typical community-acquired pneumonia
    Ian R Friedland
    Merck Research Laboratories, West Point, PA, USA
    Pulm Pharmacol Ther 17:199-203. 2004
    ..In patients with COPD as well as in the overall study population, the efficacy of ertapenem as initial antimicrobial monotherapy for patients with serious typical community-acquired pneumonia was comparable to that of ceftriaxone...
  20. ncbi request reprint In vitro susceptibilities of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: the 2003 Study for Monitoring Antimicrobial Resistance Trends (SMART)
    David L Paterson
    University of Pittsburgh Medical Center, Pittsburgh, PA, USA
    J Antimicrob Chemother 55:965-73. 2005
    ....
  21. pmc Unexpectedly high burden of rotavirus gastroenteritis in very young infants
    H Fred Clark
    Division of Infectious Diseases, The Children s Hospital of Philadelphia, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    BMC Pediatr 10:40. 2010
    ..The purpose of our study was to assess the age distribution of children with confirmed community-acquired rotavirus gastroenteritis presenting to an urban referral hospital...
  22. doi request reprint An unusual outbreak of rotavirus genotype G2P[6] during the 2005-2006 epidemic season in Philadelphia
    H Fred Clark
    The Children s Hospital of Philadelphia, Philadelphia, PA, USA
    Diagn Microbiol Infect Dis 70:218-22. 2011
    ..The large majority of G2 strains had the rare P[6] genotype. Urban African-American children under 6 months of age were disproportionately affected...
  23. ncbi request reprint Impact of indinavir on the quality of life in patients with advanced HIV infection treated with zidovudine and lamivudine
    Paul M Coplan
    Merck Research Laboratories, West Point, PA 19486, USA
    Clin Infect Dis 39:426-33. 2004
    ..We examined the impact of indinavir on quality of life in participants from this study...
  24. doi request reprint HIV seroconversion without infection after receipt of adenovirus-vectored HIV type 1 vaccine
    Erin K Quirk
    Merck Research Laboratories, West Point, Pennsylvania 19454 1099, USA
    Clin Infect Dis 47:1593-9. 2008
    ..We analyzed human immunodeficiency virus (HIV) seroresponses from 3 phase I HIV-1 vaccine trials to assess the frequency of vaccine-induced seroconversion...
  25. pmc Robustness of the healthcare utilization results from the Rotavirus Efficacy and Safety Trial (REST) evaluating the human-bovine (WC3) reassortant pentavalent rotavirus vaccine (RV5)
    Robbin Itzler
    Merck Research Laboratories, West Point, Pennsylvania, USA
    BMC Pediatr 10:42. 2010
    ..The paper also explores the consistency of the results for different subgroups of the study population with different types of surveillance...
  26. ncbi request reprint Incidence of myocardial infarction in randomized clinical trials of protease inhibitor-based antiretroviral therapy: an analysis of four different protease inhibitors
    Paul M Coplan
    Department of Epidemiology, Merck Research Laboratories, West Point, Pennsylvania 19486, USA
    AIDS Res Hum Retroviruses 19:449-55. 2003
    ..Although studies with a longer duration of PI therapy are in progress to assess whether a later increase in MI incidence occurs, our analysis did not demonstrate a dramatic increase in MI risk during the first year of PI therapy...
  27. pmc Susceptibilities of genotype 1a, 1b, and 3 hepatitis C virus variants to the NS5A inhibitor elbasvir
    Rong Liu
    Merck Research Laboratories, Merck and Co, Inc, Kenilworth, New Jersey, USA
    Antimicrob Agents Chemother 59:6922-9. 2015
    ..NS5A-RAVs emerged most often at amino acid positions 28, 30, 31, and 93 in both the laboratory and clinical trial. (The MK-8742 P002 trial has been registered at ClinicalTrials.gov under identifier NCT01532973.). ..
  28. doi request reprint Emergence of resistance-associated variants after failed triple therapy with vaniprevir in treatment-experienced non-cirrhotic patients with hepatitis C-genotype 1 infection: a population and clonal analysis
    Richard J O Barnard
    Merck Sharp and Dohme, Whitehouse Station, NJ, USA
    Virology 443:278-84. 2013
    ..We identified RAVs from non-cirrhotic patients failing to achieve SVR on vaniprevir-containing regimens from a dose/duration-ranging trial of triple-combination therapy...
  29. doi request reprint Virologic resistance analysis from a phase 2 study of MK-5172 combined with pegylated interferon/ribavirin in treatment-naive patients with hepatitis C virus genotype 1 infection
    Anita Y M Howe
    Merck Research Laboratories, West Point
    Clin Infect Dis 59:1657-65. 2014
    ..We analyzed variants in treatment-naive noncirrhotic patients with virologic failure on MK-5172 (100-800 mg/day) plus pegylated interferon alfa/ribavirin (peg-IFN/RBV) during a phase 2 trial...
  30. pmc Decline in cases of rotavirus gastroenteritis presenting to The Children's Hospital of Philadelphia after introduction of a pentavalent rotavirus vaccine
    H Fred Clark
    Division of Infectious Diseases, The Children s Hospital of Philadelphia, Philadelphia, Pennsylvania 19104, USA
    Clin Vaccine Immunol 16:382-6. 2009
    ..Because protection rates appeared to have exceeded vaccination rates, herd immunity may have contributed to some degree to the effectiveness of the vaccine...
  31. ncbi request reprint Treatment with indinavir, efavirenz, and adefovir after failure of nelfinavir therapy
    Alfred J Saah
    Merck Research Laboratories, West Point, PA 19486, USA
    J Infect Dis 187:1157-62. 2003
    ..Suppression to <400 viral RNA copies/mL was achieved at week 48 in 56% of patients with the D30N virus versus 18% of patients with the L90M virus...
  32. doi request reprint Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults
    Frances H Priddy
    Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA
    Clin Infect Dis 46:1769-81. 2008
    ....
  33. ncbi request reprint Recombinant plasma gelsolin diminishes the acute inflammatory response to hyperoxia in mice
    Melpo Christofidou-Solomidou
    Division of Pulmonary Medicine, Department of Medicine, University of Pennsylvania Medical School, Philadelphia, USA
    J Investig Med 50:54-60. 2002
    ..By scavenging extracellular actin and modulating the effects of lysophosphatidic acid, plasma gelsolin could serve a critical protective role against oxidant injury...
  34. ncbi request reprint Safety and tolerability of caspofungin acetate in the treatment of fungal infections
    C A Sable
    Department of Infectious Diseases, Merck Research Laboratories, West Point, Pennsylvania 19486, USA
    Transpl Infect Dis 4:25-30. 2002
    ..Caspofungin may have potentially important drug interactions with cyclosporine and tacrolimus...
  35. ncbi request reprint Indinavir did not increase the short-term risk of adverse cardiovascular events relative to nucleoside reverse transcriptase inhibitor therapy in four phase III clinical trials
    P M Coplan
    Merck Research Laboratories, West Point, PA, USA
    AIDS 15:1584-6. 2001
    ..Extrapolation of these findings is limited by the brief length of therapy and the small number of cases...
  36. doi request reprint Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection
    David A Cooper
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney
    N Engl J Med 359:355-65. 2008
    ....
  37. doi request reprint Raltegravir with optimized background therapy for resistant HIV-1 infection
    Roy T Steigbigel
    State University of New York at Stony Brook, Stony Brook, USA
    N Engl J Med 359:339-54. 2008
    ..Raltegravir (MK-0518) is an inhibitor of human immunodeficiency virus type 1 (HIV-1) integrase active against HIV-1 susceptible or resistant to older antiretroviral drugs...
  38. ncbi request reprint A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis
    Alvaro Villanueva
    Preventio, Barranquilla, Colombia
    Am J Med 113:294-9. 2002
    ..Candida esophagitis remains an important cause of morbidity in patients with advanced human immunodeficiency virus (HIV) infection. Fluconazole is widely regarded as the treatment of choice for this condition...
  39. pmc Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases
    Eduardo G Arathoon
    Hospital General San Juan de Dios, Guatemala City, Guatemala
    Antimicrob Agents Chemother 46:451-7. 2002
    ..01). Caspofungin provided a generally well-tolerated parenteral therapeutic option for HIV-infected patients with oropharyngeal and/or esophageal candidiasis in this study...
  40. ncbi request reprint Long-term efficacy, safety, and tolerability of indinavir-based therapy in protease inhibitor-naive adults with advanced HIV infection
    Martin S Hirsch
    Massachusetts General Hospital, Harvard Medical School, Boston, USA
    Clin Infect Dis 37:1119-24. 2003
    ..Hyperbilirubinemia (experienced by 31% of subjects), nausea (17%), abdominal pain (14%), and nephrolithiasis (13%) were the most common drug-related adverse events during the extension...
  41. ncbi request reprint Indinavir did not further increase mean triglyceride levels in HIV-infected patients treated with nucleoside reverse transcriptase inhibitors: an analysis of three randomized clinical trials
    Carlos Rojas
    University of North Carolina, Chapel Hill, North Carolina, USA
    Pharmacoepidemiol Drug Saf 12:361-9. 2003
    ....
  42. ncbi request reprint In vitro susceptibilities of aerobic and facultatively anaerobic Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: 2004 results from SMART (Study for Monitoring Antimicrobial Resistance Trends)
    Flavia Rossi
    Hospital das Clinicas da Faculdade de Medicina, São Paulo LIM 03, Brazil
    J Antimicrob Chemother 58:205-10. 2006
    ..This 2004 report summarizes the most recently completed annual data from SMART...
  43. ncbi request reprint Open-label study of a twice-daily indinavir 800-mg/ritonavir 100-mg regimen in protease inhibitor-naive HIV-infected adults
    Benjamin Young
    Rose Medical Center, Denver, CO, USA
    J Acquir Immune Defic Syndr 31:478-82. 2002
    ..In this study, twice-daily indinavir 800 mg/ritonavir 100 mg with two nucleoside reverse transcriptase inhibitors provided potent viral suppression and immunologic reconstitution in many PI-naive patients...
  44. ncbi request reprint In vitro susceptibilities of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections in the Asia-Pacific region: 2004 results from SMART (Study for Monitoring Antimicrobial Resistance Trends)
    Po Ren Hsueh
    Department of Laboratory Medicine and Internal Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan
    Int J Antimicrob Agents 28:238-43. 2006
    ..Of the antimicrobial agents tested, carbapenems were the most reliably active in vitro against Enterobacteriaceae recovered from patients in Asia-Pacific with intra-abdominal infections...
  45. ncbi request reprint In vitro susceptibilities of Escherichia coli isolated from patients with intra-abdominal infections worldwide in 2002-2004: results from SMART (Study for Monitoring Antimicrobial Resistance Trends)
    Grant V Bochicchio
    University of Maryland Medical System, Baltimore, Maryland, USA
    Surg Infect (Larchmt) 7:537-45. 2006
    ..Escherichia coli has been by far the most frequently isolated species...
  46. ncbi request reprint Pharmacokinetics and pharmacodynamics of ertapenem: an overview for clinicians
    David E Nix
    University of Arizona College of Pharmacy, Tucson, AZ, USA
    J Antimicrob Chemother 53:ii23-8. 2004
    ..Ertapenem is neither a substrate nor an inhibitor of P-glycoprotein or cytochrome P450 enzymes; significant drug interactions between ertapenem and drugs handled by these systems are not expected...
  47. ncbi request reprint Infective endocarditis
    Mark J DiNubile
    N Engl J Med 346:782-3. 2002
  48. ncbi request reprint Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine
    Timo Vesikari
    University of Tampere Medical School, Tampere, Finland
    N Engl J Med 354:23-33. 2006
    ..Rotavirus is a leading cause of childhood gastroenteritis and death worldwide...
  49. ncbi request reprint Erectile dysfunction in an urban HIV-positive population
    Alexander R Ende
    Jonathan Lax Center, Philadelphia FIGHT, Philadelphia, Pennsylvania 19107, USA
    AIDS Patient Care STDS 20:75-8. 2006
    ..These results emphasize the high prevalence of ED in HIV-positive men...
  50. ncbi request reprint Corticosteroids in ARDS
    Mark J DiNubile
    N Engl J Med 355:317-8; author reply 318-9. 2006
  51. ncbi request reprint Plasma gelsolin: in search of its raison d'etre. Focus on "Modifications of cellular responses to lysophosphatidic acid and platelet-activating factor by plasma gelsolin"
    Mark J DiNubile
    Am J Physiol Cell Physiol 292:C1240-2. 2007
  52. ncbi request reprint Concomitant use of an oral live pentavalent human-bovine reassortant rotavirus vaccine with licensed parenteral pediatric vaccines in the United States
    Zoe M Rodriguez
    Clinical Research Center, University of Puerto Rico School of Medicine, San Juan, PR
    Pediatr Infect Dis J 26:221-7. 2007
    ..Possible interactions between PRV and concomitantly administered licensed pediatric vaccines were investigated in a United States-based nested substudy (Concomitant Use Study) of the Rotavirus Efficacy and Safety Trial...